An Expert Overview of Immunotherapy for Advanced HCC
Listen to Amit G. Singal, MD, MS, and Lipika Goyal, MD, as they provide a succinct discussion of key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma.
Decera Clinical Education Oncology Podcast · Amit G. Singal MD MS, Lipika Goyal MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Link to CME: Claim Credit
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:
- Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
- Use of nivolumab ± ipilimumab and pembrolizumab
- Emerging immunotherapy combinations currently being investigated in clinical trials
- Management of key adverse events with immune checkpoint inhibitors
Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
http://bit.ly/39V6s72
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.